AELIX Therapeutics
http://www.aelixtherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AELIX Therapeutics
Hong Kong's Immuno Cure Emerges With DNA Vaccine Approach To HIV
Hong Kong-based Immuno Cure expects its therapeutic DNA vaccine for HIV/AIDS will soon deliver early Phase I results in patients with late-stage infections, CEO Xia Jin tells Scrip in an interview, also touching on the local biotech ecosystem.
From Treatment To Prevention To A Cure: An Interview With Gilead’s HIV R&D Leaders
Gilead execs Jared Baeten and Tomas Cihlar talk to Scrip about how the company, still the leader in HIV, is working toward less-frequent dosing, providing PrEP for broader populations and maybe finding a cure for HIV infection.
The Biotech Rollercoaster Ride: From Lab To Buyout
After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.
Aelix Therapeutics' Multi-Vector Therapeutic HIV Vaccine Could Be Backbone Of Combination Strategy
Emerging Company Profile: Aelix Therapeutics has constructed a potential therapeutic HIV vaccine to refocus the immune system onto vulnerable parts of the virus, and may allow patients to control viral replication without antiretroviral therapy.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice